Aurora Cannabis rebuts Curaleaf statements on hostile bid, says claims inaccurate

• Aurora Cannabis corrected what it called inaccurate statements in Curaleaf’s unsolicited takeover bid materials.
• Shareholders were told to take no action while the board and a special committee review the offer.
• Aurora said international net revenue rose 17% year over year in fiscal Q1 2027, with Germany a key driver.
• It disputed Curaleaf’s claims on German reimbursement exposure, citing less than 10% of German volume before regulatory changes.
• Aurora rejected Curaleaf’s criticism of cultivation performance, calling it outdated and pointing to expanded EU-GMP capacity over five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurora Cannabis Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202608240705CANADANWCANADAPR_C0777) on August 24, 2026, and is solely responsible for the information contained therein.